Allogene Therapeutics announced management turnover, with CMO Zachary Roberts set to succeed David Chang as president and CEO on June 1. Chang, an Allogene co-founder, will stay on the board after an eight-year run leading the off-the-shelf cell therapy company. The leadership shift arrives as the field continues to evaluate next-generation allogeneic platforms, manufacturing scale-up, and clinical differentiation—areas where CMO and R&D leadership typically shape trial direction and partnering strategies.